Psych MEQs / SAQs · Psychopharmacology — metabolic syndrome and psychotropic monitoring
Metabolic syndrome risk, monitoring and metformin after olanzapine (MEQ)
FRANZCP-style MEQ integrating MetS criteria, agent ranking, ADA/APA monitoring, early intervention and the clozapine exception.
On this page & tools
Target exams
Model answer
Reveal model answer
(i) Metabolic syndrome components. Cluster of central adiposity (waist), elevated triglycerides, low HDL-C, elevated blood pressure and elevated fasting glucose. NCEP-style teaching uses three or more components; IDF emphasises waist as a required entry criterion plus two further factors. This man already shows rapid central weight gain, rising glucose into the impaired range and hypertriglyceridaemia — a clear adverse cardiometabolic trajectory even if formal MetS criteria are still accruing.[8][1]
(ii) Hierarchy and mechanisms. Olanzapine ranks with clozapine in the highest metabolic liability tier for weight, diabetes and dyslipidaemia. Mechanisms include H1 and 5-HT2C antagonism (appetite/satiety), reduced activity from sedation, and insulin-resistance/lipid pathway effects beyond kilograms alone.[2][3][7]
(iii) Monitoring schedule. ADA/APA skeleton: baseline weight/BMI, waist, BP, fasting glucose/HbA1c and lipids; weight at 4, 8 and 12 weeks then quarterly; recheck glucose, lipids and BP at about 12 weeks and at least annually, sooner if rapid gain or symptoms. He should already have had the 4- and 8-week weight checks that detected this trajectory.[1]
(iv) Immediate management. Shared decision; intensify lifestyle (diet, activity, sleep, smoking if relevant); consider switch to a lower-metabolic agent (e.g. aripiprazole) with cross-taper while psychosis remains controlled; consider metformin adjunct — teaching start 500 mg orally daily or twice daily with food, titrate toward 1000–2000 mg/day if eGFR allows, check contraindications and counsel GI effects (Wu; Jarskog METS). Treat emerging prediabetes/lipids with GP/endocrine standards; safety-net symptomatic hyperglycaemia.[4][5][6][1]
(v) If clozapine were required for TRS. Do not automatically stop unique TRS efficacy for metabolic fear alone. Use intensive monitoring, lifestyle, metformin, cardiometabolic medicines and documented shared decision; coordinate physical health aggressively. Metabolic management becomes more intense rather than abandonment of the only highly effective agent.[7][5]
Common errors
Do not wait for polyuria before acting on 6.5 kg early gain; do not claim all SGAs are metabolically identical; do not start metformin without renal/safety thinking; do not stack a second high-metabolic antipsychotic; and do not treat clozapine as casually interchangeable with olanzapine for TRS.[1][2][5][7]
References
- [1]American Diabetes Association, American Psychiatric Association, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes Diabetes Care, 2004.PMID 14747245
- [2]Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis Am J Psychiatry, 1999.PMID 10553730
- [3]Newcomer JW, Haupt DW The metabolic effects of antipsychotic medications Can J Psychiatry, 2006.PMID 16933585
- [4]Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial JAMA, 2008.PMID 18182600
- [5]Jarskog LF, Hamer RM, Catellier DJ, et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder Am J Psychiatry, 2013.PMID 23846733
- [6]Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine J Clin Psychiatry, 2008.PMID 18605811
- [7]De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs Nat Rev Endocrinol, 2011.PMID 22009159
- [8]Alberti KG, Zimmet P, Shaw J Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation Diabet Med, 2006.PMID 16681555